- Home
- BLFY vs NGEN Comparison
BLFY vs NGEN Comparison
Compare BLFY & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | BLFY | NGEN |
|---|---|---|
| Founded | 1939 | 2017 |
| Country | United States | Canada |
| Employees | N/A | 9 |
| Industry | Commercial Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 298.3M | 314.8M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | BLFY | NGEN |
|---|---|---|
| Price | $13.21 | $3.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | ★ 699.9K | 151.8K |
| Earning Date | 04-29-2026 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.27 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $19.85 | N/A |
| Revenue Next Year | $20.18 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.61 | $3.51 |
| 52 Week High | $14.74 | $5.93 |
Technical Indicators
Market Signals| Indicator | BLFY | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 54.31 | 40.76 |
| Support Level | $12.37 | $3.59 |
| Resistance Level | $13.55 | $4.44 |
| Average True Range (ATR) | 0.32 | 0.20 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 95.05 | 12.37 |
Price Performance
Historical ComparisonAbout BLFY Blue Foundry Bancorp
Blue Foundry Bancorp is a full-service bank. Its business consists of originating one-to-four-family residential, multi-family, and non-residential real estate mortgages, home equity loans and lines of credit, and commercial and industrial loans. It attracts retail deposits from the general public in the areas surrounding its banking offices, through its borrowers, and through its online presence, offering a wide variety of deposit products. The bank also invests in securities. Its revenues are derived from interest on loans and, to a lesser extent, interest on mortgage-backed and other investment securities. The company's sources of funds are deposits, principal, and interest payments on loans, securities, and borrowings from the Federal Home Loan Bank of New York.
About NGEN NervGen Pharma Corp. Common stock
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.